VX-264

Question 1

Paul Langerhans identified the role of pancreatic islets in producing insulin in 1869.

Answer 1

FALSE

Question 2

The FDA approved the use of recombinant DNA technology to produce synthetic human insulin for medical use in 1982, providing a safer and more efficient alternative to animal insulin.

Answer 2

TRUE

Question 3

VX-880 is a stem cell-derived pancreatic islet cell therapy developed that requires immunosuppression.

Answer 3

TRUE

Question 4

VX-264 is a non-encapsulated cell-derived pancreatic islet cell therapy to bypass immunosuppression.

Answer 4

FALSE

Question 5

In 2024, ViaCyte officially extended its collaboration with CRISPR Therapeutics.

Answer 5

FALSE

Question 6

Lack of insulin results in an decrease in the circulating level of blood glucose

Answer 6

FALSE

Question 7

The transplantation of allogeneic pancreatic beta cells obtained through hESC differentiation needs immunosuppression

Answer 7

TRUE

Question 8

These autoantibodies usually appear after 25 years of age

Answer 8

FALSE

Question 9

Traditional methods of Type 1 Diabetes (T1D) involve the infusion of pancreatic stem cells into the portal vein of the liver, requiring the patients to take immunosuppressive drugs to prevent tissue rejection.

Answer 9

FALSE

Question 10

Pancreatic islets derive from pancreatic endocrine cells, which are differentiated from embryonic pluripotent cells.

Answer 10

FALSE

Question 11

Pancreatic islet principal function is the secretion of insulin in response to glucose. It is composed mainly of Ⲁ, β and δ cells.

Answer 11

TRUE

Question 12

Encapsulation approaches are designed to generate an environment that allows insulin secretion of the transplanted cells preventing immune system attacks.

Answer 12

TRUE

Question 13

PEC-Encap is a type of microencapsulation that contains human embryonic stem cells derived from pancreatic precursor cells.

Answer 13

FALSE

Question 14

The photoinitiated polymerization method used in PEC-Encap involves irradiating the polymer solution containing the cells with UV light to trigger the polymerization, resulting in a stable encapsulating matrix.

Answer 14

TRUE

Question 15

The encapsulated insulin-producing cells in VX-264 respond to increased glucose levels, releasing insulin into the bloodstream, mimicking the action of the natural alpha-pancreatic cells.

Answer 15

FALSE

Question 16

The photoinitiator dye is conjugated to the photoactive polymer, so when it is exposed to UV light triggers the cross-linking reaction between the polymers.

Answer 16

FALSE

Question 17

VX-264 requires immunosuppressive drugs to enhance and maintain the insulin-producing cells function and viability over the time.

Answer 17

FALSE

Question 18

The modifications in CTX-211 are fully designed for a future without encapsulation devices.

Answer 18

FALSE

Question 19

Adding CD59 to islet cells would protect them from complement-mediated immune attacks.

Answer 19

TRUE

Question 20

CTX-211 from CRISPR Therapeutics uses iPSC-derived islet cells that have been genetically modified to avoid immune system attacks.

Answer 20

TRUE